Safety and Effectiveness: February 2007 Archives

vaccineAtlanta, GA -- The Advisory Committee on Immunization Practices (ACIP) will meet tomorrow at the CDC in Atlanta. Thimerosal, a controversial mercury- based vaccine preservative still used in flu shots, will be discussed. Health Reporters are encouraged to attend. Lyn Redwood of the National Autism Association and the Coalition for SafeMinds will be in attendance and available to speak with members of the press.

WHAT:
The Advisory Committee on Immunization Practices (ACIP) Meeting

WHEN:
Tomorrow, February 21st and Thursday, February 22nd from 7:00a.m.-6:00p.m.
Ethylmercury Thimerosal is scheduled to be discussed tomorrow at 10:55 am. 

Vaccine Safety Group Releases GARDASIL Reaction Report

|
NATIONAL VACCINE INFORMATION CENTERWashington, D.C. - The National Vaccine Information Center (NVIC) today released a new analysis of the federal Vaccine Adverse Event Reporting System (VAERS) reports of serious health problems following HPV vaccination (Merck's GARDASIL) during the last six months of 2006. Out of the 385 individual GARDASIL adverse event reports made to VAERS, two-thirds required additional medical care and about one-third of all reports were for children 16-years-old and under, with nearly 25 percent of those children having received simultaneously one or more of the 18 vaccines that Merck did not study in combination with GARDASIL. NVIC is calling on the FDA and CDC to warn parents and doctors that GARDASIL should not be combined with other vaccines and that young girls should be monitored for at least 24 hours for syncopal (collapse/fainting) episodes that can be accompanied by seizure activity, as well as symptoms of tingling, numbness and loss of sensation in the fingers and limbs, all of which should be reported to VAERS immediately.